Global Pharmacovigilance Market - Forecasts From 2018 to 2023
The global Pharmacovigilance market is expected to reach US$6.705 billion by 2023 from US$3.224 billion in 2017 growing at a CAGR of 12.98%. Pharmacovigilance as defined by the WHO is the “science and activities relating to the detection, assessment, understanding and prevention of adverse events or any other drug-related problem.” Adverse Events is any “untoward medical occurrence” which happens to either a patient or a subject in a clinical investigation when a pharmaceutical product has been given to that person. The aim of the pharmacovigilance is to enhance patient care and patient safety in relation to the use of medicines; and to provide reliable, balanced information for the effective assessment of the risk-benefit profile of medicines. The market is expected to show significant growth during the forecast period owing to the rising drug development and number of drugs under investigation. Rising incidences of the adverse drug reaction coupled with stringent government regulations to monitor them have also boosted the market for pharmacovigilance. However, lack of patient data security and safety might hamper the growth of the pharmacovigilance market during the given time frame. Adopting a global approach for pharmacovigilance assessment has also been a major challenge for the pharmacovigilance industry.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Pharmacovigilance market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Pharmacovigilance market.
Major industry players profiled as part of the report are Cognizant, Bioclinica and Kinapse among others.
Segmentation
By Clinical Trial Phase
Preclinical
Phase I
Phase II
Phase III
Phase IV (Post Marketing Surveillance)
By Service Provider
Contract Outsourcing
In House
By End User
Pharmaceutical and Biopharmaceuticals
Medical Devices
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Pharmacovigilance market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Pharmacovigilance market.
Major industry players profiled as part of the report are Cognizant, Bioclinica and Kinapse among others.
Segmentation
By Clinical Trial Phase
Preclinical
Phase I
Phase II
Phase III
Phase IV (Post Marketing Surveillance)
By Service Provider
Contract Outsourcing
In House
By End User
Pharmaceutical and Biopharmaceuticals
Medical Devices
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY CLINICAL TRIAL PHASE
5.1. Preclinical
5.2. Phase I
5.3. Phase II
5.4. Phase III
5.5. Phase IV (Post Marketing Surveillance)
6. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY SERVICE PROVIDER
6.1. Contract Outsourcing
6.2. In House
7. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY END USERS
7.1. Pharmaceutical and Biopharmaceuticals
7.2. Medical Devices
8. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Cognizant
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Kinapse (A Syneos Health Company)
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Sciformix (A Covance Company)
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. Quintiles IMS
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Pharmaceutical Product Development, LLC.
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Oviya MedSafe
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. APCER Life Sciences, Inc.
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Navitas Life Sciences
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Bioclinica
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY CLINICAL TRIAL PHASE
5.1. Preclinical
5.2. Phase I
5.3. Phase II
5.4. Phase III
5.5. Phase IV (Post Marketing Surveillance)
6. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY SERVICE PROVIDER
6.1. Contract Outsourcing
6.2. In House
7. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY END USERS
7.1. Pharmaceutical and Biopharmaceuticals
7.2. Medical Devices
8. GLOBAL PHARMACOVIGILANCE MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Cognizant
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Kinapse (A Syneos Health Company)
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Sciformix (A Covance Company)
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. Quintiles IMS
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Pharmaceutical Product Development, LLC.
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Oviya MedSafe
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. APCER Life Sciences, Inc.
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Navitas Life Sciences
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Bioclinica
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
